摘要
目的初步探析木犀草素联合替莫唑胺对脑胶质瘤大鼠生长、血管生成及血管NF—KB表达水平的影响，为胶质瘤的防治提供新思路。方法120只雌性Wistar大鼠进行实验。30只做体外实验确定最佳处理条件。另外90只分为3组并进行造模，分别用木犀草素、替莫唑胺、木犀草素联合替莫唑胺进行处理，比较各组细胞周期（G2／M所占比例）、血管内皮生长因子（VEGF）表达及血管NF—KB表达。结果联合处理组的G2／M所占比例、VEGF、NF—κB分别为（3．6±1．6）％、（16．2±2．5）％、（347．7±70．2）mm2，分别低于木犀草素处理组和替莫唑胺处理组，差异有统计学意义（P〈0．05）。同时木犀草素处理组的G2／M所占比例、VEGF、NF—KB也低于替莫唑胺处理组，差异有统计学意义（P〈0．05）。结论木犀草素可多靶点、多环节、多途径抑制肿瘤，且可透过血脑屏障，对细胞周期、VEGF和NF—κB表达均有明显抑制作用，与替莫唑胺联合应用治疗脑胶质瘤可取得较佳效果，值得进一步展开深入研究。
Objective To preliminarily explore the effects of luteolin combined with Temozolomide on growth, angiogenesis and expression level of vascular NF-KB in rats with brain gliomas and provide new ideas for the prevention and treatment of gliomas. Methods 120 female Wistar rats were used for experiment. The optimal treatment conditions were determined by 30 rats in vitro experiment. Another 90 rats were divided into three groups and were used for modeling. The three groups were treated with luteolin, Temozolomide and luteolin combined with Tcmozolomide, respectively. The cell cycle （proportion of G2/M）, expression of vascular endothelial growth factor （VEGF） and expression of vascular NF-KB were compared. Results In the combined treatment group, the pro- portion of G2/M, VEGF and NF-KB[（3.6~l.6）%, （16.2＋2.5）%, （347.7：~70.2）mm2] were lower than those in luteolin treatment group and Temozolomide treatment group respectively （P〈O.05）. Besides, the proportion of G2/M, VEGF and NF-KB in luteolin treatment group were lower than those in Temozolomide treatment group （P〈O.05）. Conclusion Luteolin can inhibit tumor through multi-target, multi-link and multiple ways. Besides, it can also significantly inhibit cell cycle, expression of VEGF and NF-KB through blood brain barrier. Its combination with Temozolomide in the treatment of glioma can achieve a better effect, which is worthy of further study.
出处
《中国心血管病研究》
CAS
2017年第2期186-189,I0002,共5页
Chinese Journal of Cardiovascular Research
